Message : Required fields First Data Presented Showcasing Autobahn’s Novel FAAH-Mediated Prodrug Approach for Selective Delivery of Thyromimetics to the Brain Treatment with ABX-002 Leads to Reductions in VLCFA in Brain Tissue and Plasma in AMN Mouse Model Autobahn Therapeutics, a biotechnology company focused on restoring hope for people affected by CNS disorders, today announced the presentation of preclinical data of ABX-002, a CNS-penetrating prodrug that provides a balanced delivery of LL-340001, a potent and selective thyroid hormone receptor beta (TRβ) agonist, for the potential treatment of adrenomyeloneuropathy (AMN), a progressive and debilitating rare disease. The data will be highlighted in a poster presentation at the American Academy of Neurology Annual Meeting, which is being held virtually from April 17-22, 2021. Posters will be made available at the start of the conference and remain viewable online through the virtual forum for 30 days after the meeting.